4D Molecular Therapeutics Inc Dossier
Qualitative Analysis
Business overview
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) is a leading late-stage clinical biopharmaceutical company focused on inventing and developing genetic medicines using its proprietary Therapeutic Vector Evolution platform. The company's platform utilizes directed evolution to invent customized and evolved adeno-associated virus (AAV) vectors designed to target specific tissues and overcome the limitations of traditional gene therapies. 4DMT's clinical pipeline is primarily focused on large-market diseases in ophthalmology and pulmonology. Its lead product candidate, 4D-150, is designed as a single-dose intravitreal genetic medicine that provides multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) to treat blinding retinal vascular diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its second priority candidate, 4D-710, is an aerosolized genetic medicine designed to deliver the CFTR transgene to the lungs of patients with cystic fibrosis.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
In January 2025, 4DMT implemented a strategic pipeline prioritization to focus resources on its lead late-stage candidates, 4D-150 (retinal vascular diseases) and 4D-710 (cystic fibrosis lung disease). As part of this initiative, the company executed a restructuring that reduced its workforce by approximately 25% and paused internal funding for other clinical-stage candidates (4D-175, 4D-725, and 4D-310) pending external partnerships.
Expected impact: Extends cash runway into the second half of 2028 and concentrates capital on high-value late-stage clinical programs.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases (including wet AMD and DME) in the Asia-Pacific region (including Japan, China, and Australia). 4DMT retains full rights in the US, Europe, and Latin America.
Terms: $85 million upfront payment received in Q4 2025, with at least $50 million in expected development cost-sharing over three years, up to $336 million in potential regulatory and commercial milestones, and tiered double-digit royalties on net sales.
Accelerates the clinical development of 4D-710 for the treatment of cystic fibrosis lung disease in both modulator-eligible and ineligible patient populations.
Terms: Equity investment of up to $11 million in two tranches, with the first tranche of $7.5 million received upfront in October 2025.